CUPERTINO, Calif., Oct 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present on technologies for targeted
drug delivery at the Techvest 3rd Annual Conference on Tissue Repair,
Replacement and Regeneration (TR3). The conference is scheduled for October 23rd
and 24th at the Hilton New York. Randolph M. Johnson, Ph.D., Vice President of
Preclinical Research and Director of Central Nervous System Programs at DURECT
will be presenting at the conference on Wednesday, October 24, 2001 at 2:20 p.m.
The presentation will be webcast live from the Techvest 3rd Annual Healthcare
Conference. The webcast (audio only) will be available on DURECT’s website at
http://www.www.durect.com under the Calendar of Event section of “Investor
Relations.” The presentation will also be available for replay on DURECT’s
website for a period of 30 days after the conference. To join DURECT’s email
alert service and receive advance notice of these and other events, please
register by selecting “Email Alerts” on the main Investor Relations web page at
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems for the treatment of chronic debilitating diseases and
enabling biotechnology-based pharmaceutical products. DURECT’s goal is to
deliver the right drug to the right site in the right amount at the right time.
DURECT’s pharmaceutical systems combine technology innovations from the medical
device and drug delivery industries with proprietary pharmaceutical and
biotechnology drug formulations. These capabilities can enable new drug
therapies or optimize existing therapies based on a broad range of compounds,
including small molecule pharmaceuticals as well as biotechnology molecules such
as proteins, peptides and genes. DURECT focuses on the treatment of chronic
diseases including pain, CNS disorders, cardiovascular disease and cancer.
DURECT is holding an exclusive license from ALZA Corporation to develop and
commercialize products in selected fields based on the DUROS(R) implant
technology. Chronogesic(TM), a 3-month continuous infusion subcutaneous implant
for the treatment of chronic pain, is the first product in this series and
completed phase II testing in June, 2001. DURECT also owns three proprietary
erodible implant platform technologies, including SABER(TM), a patented and
versatile depot injectable useful for protein delivery. DURECT also
commercializes IntraEAR(R) catheters which have been used by physicians to treat
inner ear disorders.
Founded in 1998, DURECT is headquartered in Cupertino, CA. The company’s World
Wide Web site can be accessed at http://www.www.durect.com . To join DURECT’s email
alert service, please register by selecting “Email Alerts” on the main Investor
Relations web page at http://www.www.durect.com .
NOTE: Chronogesic(TM), SABER(TM) and IntraEAR(R) are trademarks of DURECT
Corporation. DUROS(R) is a trademark of ALZA Corporation.
The statements in this press release regarding DURECT’s products in development,
product development plans, expected product benefits or potential product
markets are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but are
not limited to, DURECT’s ability to successfully complete clinical trials,
develop, manufacture and commercialize its products, obtain product and
manufacturing approvals from regulatory agencies, validate and qualify a
manufacturing facility and manage its growth and expenses, as well as
marketplace acceptance of DURECT’s products. Further information regarding these
and other risks is included in DURECT’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2001 filed with the SEC on August 14, 2001, and Annual
Report on Form 10-K for the fiscal year ended December 31, 2000 filed with the
SEC on March 30, 2001, under the heading “Factors that may effect future
SOURCE DURECT Corporation
Schond L. Greenway, Senior Director, Investor Relations and Strategic Planning of DURECT Corporation, +1-408-777-1417,
Copyright (C) 2001 PR Newswire. All rights reserved.